Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
102.6 USD | +0.07% | +1.10% | +9.82% |
Apr. 15 | MC Healthcare, Inc. acquired FreeIll Co., Ltd. from ORIX Corporation. | CI |
Apr. 04 | S&P Global Ratings Cuts Orix's Rating, Outlook Remains Stable | MT |
Strengths
- With a P/E ratio at 11.09 for the current year and 9.37 for next year, earnings multiples are highly attractive compared with competitors.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- One of the major weak points of the company is its financial situation.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Consumer Lending
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.82% | 23.38B | - | ||
-8.14% | 49.88B | C+ | ||
-5.25% | 30.53B | C+ | ||
+16.97% | 17.94B | B | ||
-6.99% | 11.81B | C+ | ||
+21.92% | 11.27B | B- | ||
-20.90% | 8.31B | - | ||
+14.34% | 8.13B | C | ||
+36.65% | 6.39B | C- | ||
+3.43% | 6.09B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 8591 Stock
- IX Stock
- Ratings ORIX Corporation